Carbapenems are often used to treat infections in obstetrics and gynaecology because of their activity against anaerobes. S-4661, a new injectable carbapenem antibiotic, has favourable pharmacokinetic properties and is not hydrolysed by dehydropeptidase I. We investigated the in vitro and in vivo antibacterial activities of S-4661 against strains of Streptococcus agalactiae, Escherichia coli, Peptostreptococcus magnus, Bacteroides fragilis and Prevotella bivia, which are major pathogens in the fields of obstetrics and gynaecology. The MIC 50 and MIC 90 of S-4661 for these strains were 0.25 and 1 mg/L, respectively. The in vivo efficacy of S-4661 was evaluated in a rat model of intrauterine infection, namely pyometra caused by E. coli and B. fragilis. The accumulation of neutrophils in the uterus in the S-4661-treated group was less marked and the number of bacteria significantly lower than those in the untreated group. These results suggest that S-4661 may be useful for treating polymicrobial infections in the fields of obstetrics and gynaecology. agar (Difco Laboratories, Detroit, MI, USA); S. agalactiae on Mueller-Hinton agar (Difco) supplemented with 5% sheep serum (Irvine Scientific, Santa Ana, CA, USA); P. magnus and B. fragilis on modified Gifu anaerobic medium (GAM) agar (Nissui Pharmaceutical Co., Tokyo, Japan); and P. bivia on Brucella HK agar (Kyokuto Pharmaceutical Co., Tokyo, Japan) supplemented with 5% laked sheep blood. They were then suspended in MuellerHinton broth (Difco) or GAM broth at c. 5 ϫ 10 8 cfu/mL. After 200-fold dilution of the suspension, the bacteria were inoculated on to appropriate agar plates containing each antimicrobial agent (at concentrations ranging from 0.0020 to 256 mg/L) with a multipoint inoculator (Microplanter, Sakuma Seisakusho, Tokyo, Japan) providing an inoculum of c. 2.5 ϫ 10 6 cfu/spot. All aerobic cultures were incubated at 37°C for 24 h and all anaerobic cultures at 37°C for 48 h in an Anaero Pack (Mitsubishi Gas Chemical Co., Tokyo, Japan). MICs were defined as the lowest concentrations of antimicrobial agents that prevented visible growth of organisms.
Introduction
Carbapenems are broad-spectrum antimicrobial agents with strong bactericidal activity; many have been developed and are widely used for clinical treatment.
1 S-4661 is a new carbapenem developed by Shionogi Co. Ltd, Osaka, Japan. 2, 3 Preliminary reports indicate that S-4661 has activity against a broad bacterial spectrum, has favourable pharmacokinetic properties and is not hydrolysed by dehydropeptidase I (DHP-I). 4 Since S-4661 is not degraded by DHP-I, the clinical use of this drug does not require the addition of a DHP-I inhibitor such as cilastatin. 4 The objective of this study was to examine the in vitro and in vivo activities of S-4661 against pathogens responsible for many infections in obstetrics and gynaecology.
Materials and methods

In vitro study
Antimicrobial agents. S-4661 was provided by Shionogi Co. Ltd, Osaka, Japan; imipenem by Banyu Pharmaceutical Co. Ltd, Tokyo, Japan; panipenem by Sankyo Co. Ltd, Tokyo, Japan; meropenem by Sumitomo Pharmaceutical Co. Ltd, Tokyo, Japan; and ceftazidime by Nippon Glaxo Co. Ltd, Tokyo, Japan. , Tokyo, Japan) supplemented with 5% laked sheep blood. They were then suspended in MuellerHinton broth (Difco) or GAM broth at c. 5 ϫ 10 8 cfu/mL. After 200-fold dilution of the suspension, the bacteria were inoculated on to appropriate agar plates containing each antimicrobial agent (at concentrations ranging from 0.0020 to 256 mg/L) with a multipoint inoculator (Microplanter, Sakuma Seisakusho, Tokyo, Japan) providing an inoculum of c. 2.5 ϫ 10 6 cfu/spot. All aerobic cultures were incubated at 37°C for 24 h and all anaerobic cultures at 37°C for 48 h in an Anaero Pack (Mitsubishi Gas Chemical Co., Tokyo, Japan). MICs were defined as the lowest concentrations of antimicrobial agents that prevented visible growth of organisms.
In vivo study
Animals. Female Sprague-Dawley rats (specific pathogen free, 6 weeks old, weighing 155-170 g) (Nippon Bio-Supply Centre, Tokyo, Japan) were used.
Organisms. Organisms were clinical isolates from patients with uterine endometritis. The MICs of S-4661 and imipenem for E. coli GOG 0020 were both 0.0125 mg/L, while those for B. fragilis GOG 3102 were both 0.10 mg/L.
Experimental animal model. 7, 8 Rats were anaesthetized with sodium pentobarbital 25 mg/kg ip. Abdominal and flank hair was shaved, then the abdominal wall was thoroughly swabbed with povidone-iodine. A small vertical incision was made in the prepared abdominal wall and the uterus and adnexa were exposed. The uterine cervix was ligated with 1-0 silk. A 24 h culture of E. coli and 48 h culture of B. fragilis on Mueller-Hinton agar and modified GAM agar, respectively, and GAM broth as an inoculating medium, were used for inoculation. With a disposable ster- 
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ile tuberculin syringe and a 27-gauge needle, 0.05 mL of bacterial suspension (4.3 ϫ 10 5 cfu/rat of E. coli and 4.1 ϫ 10 5 cfu/rat of B. fragilis) was injected into the right side of the uterine cavity. The abdominal wall was closed with 1-0 silk suture. After the operation, the abdominal wound was disinfected daily with povidone-iodine.
Therapeutic study. Sixteen hours after bacterial inoculation, the rats were treated with S-4661 10 mg/kg iv tds for 5 days or with imipenem 10 mg/kg supplemented with cilastatin 10 mg/kg iv tds for 5 days; they were then compared with an untreated control group (six rats in each group). At 136 h after bacterial inoculation, the rats were anaesthetized with sodium pentobarbital, the peritoneal cavity was opened aseptically and bacterial counts of the uterine contents were performed using BTB agar (Eiken Chemical Co. Ltd,Tokyo, Japan) for E. coli and modified GAM agar for B. fragilis.
Statistical analysis.
Values are reported as mean Ϯ S.D. All results were analysed using Fisher's protected least significance difference test and P values of Ͻ0.05 were considered significant. Table II shows the bacteriological effects of S-4661 and imipenem/cilastatin against polymicrobial infections caused by E. coli and B. fragilis in the rat pyometra model. The bacteriological response was significantly greater for the S-4661 group than for the imipenem/cilastatin and untreated groups. The effects of S-466110 mg/kg iv tds were equivalent to those of imipenem/cilastatin 10 mg/kg iv tds. S-4661 has shown similar efficacy in animal models of localized infections. 9, 10 The accumulation of neutrophils in the uterus in the S-4661 (1596.6 Ϯ 368.4 cells/mm 2 ) and imipenem/cilastatin (1625.6 Ϯ 409.0 cells/mm 
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